Insulin icodec is a novel once-weekly basal insulin analog. This trial investigated the efficacy and safety of icodec using different once-weekly titration algorithms. RESEARCH DESIGN AND METHODS This was a phase 2, randomized, open-label, 16-week, treat-to-target study. Insulin-naïve adults (n = 205) with type 2 diabetes and HbA1c 7–10% while treated with oral glucose-lowering medications… Continue reading A Randomized, Open-Label Comparison of Once-Weekly #Insulin Icodec Titration Strategies Versus Once-Daily Insulin Glargine U100
Tag: Diabetes
VPS39-deficiency observed in type 2 #diabetes impairs #muscle stem cell differentiation via altered autophagy and epigenetics
Insulin resistance and lower muscle quality (strength divided by mass) are hallmarks of type 2 diabetes (T2D). Here, we explore whether alterations in muscle stem cells (myoblasts) from individuals with T2D contribute to these phenotypes. We identify VPS39 as an important regulator of myoblast differentiation and muscle glucose uptake, and VPS39 is downregulated in myoblasts… Continue reading VPS39-deficiency observed in type 2 #diabetes impairs #muscle stem cell differentiation via altered autophagy and epigenetics
Association of Type 2 #Diabetes Mellitus and Glycemic Control With Intracranial Plaque Characteristics in Patients With Acute Ischemic #Stroke
Type 2 diabetes mellitus (T2DM) has shown to be associated with carotid plaque vulnerability. However, the impact of T2DM on intracranial artery atherosclerosis is not well‐understood. Purpose To evaluate the association of diabetes and glycemic control with intracranial atherosclerotic plaque characteristics identified by three‐dimensional contrast enhanced MR vessel wall imaging in patients after acute ischemic… Continue reading Association of Type 2 #Diabetes Mellitus and Glycemic Control With Intracranial Plaque Characteristics in Patients With Acute Ischemic #Stroke
#Semaglutide 2·4 mg once a week in adults with #overweight or #obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial
Background This trial assessed the efficacy and safety of the GLP-1 analogue once a week subcutaneous semaglutide 2·4 mg versus semaglutide 1·0 mg (the dose approved for diabetes treatment) and placebo for weight management in adults with overweight or obesity, and type 2 diabetes. Methods This double-blind, double-dummy, phase 3, superiority study enrolled adults with… Continue reading #Semaglutide 2·4 mg once a week in adults with #overweight or #obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial
#Olfactory dysfunction predicts the development of #dementia in older patients with type 2 #diabetes
Olfactory dysfunction is associated with the transition from normal cognition to dementia in persons without type 2 diabetes. This study aimed to investigate whether olfactory dysfunction could be an early marker of future dementia in older patients with type 2 diabetes. Methods This exploratory study included 151 older Japanese outpatients with type 2 diabetes who… Continue reading #Olfactory dysfunction predicts the development of #dementia in older patients with type 2 #diabetes
#Statin use is associated with lower prevalence of advanced liver #fibrosis in patients with type 2 diabetes
Patients with type 2 diabetes (T2D) are at increased risk of both cardiovascular disease (CVD) and advanced liver fibrosis related to non-alcoholic fatty liver disease (NAFLD). Statin use is known to reduce the incidence of CVD while evidence on an effect on NAFLD severity is limited. Methods This is a cross-sectional study performed with data… Continue reading #Statin use is associated with lower prevalence of advanced liver #fibrosis in patients with type 2 diabetes
Risk for recurrent #cardiovascular disease events among patients with #diabetes and chronic kidney disease
Adults who have experienced multiple cardiovascular disease (CVD) events have a very high risk for additional events. Diabetes and chronic kidney disease (CKD) are each associated with an increased risk for recurrent CVD events following a myocardial infarction (MI). Methods We compared the risk for recurrent CVD events among US adults with health insurance who… Continue reading Risk for recurrent #cardiovascular disease events among patients with #diabetes and chronic kidney disease
A Pragmatic, Randomized Clinical Trial of Gestational #Diabetes Screening
Gestational diabetes mellitus is common and is associated with an increased risk of adverse maternal and perinatal outcomes. Although experts recommend universal screening for gestational diabetes, consensus is lacking about which of two recommended screening approaches should be used. METHODS We performed a pragmatic, randomized trial comparing one-step screening (i.e., a glucose-tolerance test in which… Continue reading A Pragmatic, Randomized Clinical Trial of Gestational #Diabetes Screening
#Glucagon blockade restores functional β-cell mass in type 1 #diabetic mice and enhances function of human islets
Both type 1 and type 2 diabetes are associated with reduced β-cell mass or function, resulting from decreased proliferation and increased apoptosis. Understanding the signals governing β-cell survival and regeneration is critical for developing strategies to maintain healthy populations of these cells in individuals. Both forms of diabetes are associated with hyperglucagonemia and an increased… Continue reading #Glucagon blockade restores functional β-cell mass in type 1 #diabetic mice and enhances function of human islets
2 Medical News 